Skip to content

Age Related Effects Consuming Phaeodactylum Tricornutum

Health-promoting Effects of the Microalga Phaeodactylum Tricornutum - Bioavailability and Excretion of Nutrients in Relation to Age and Their Effects on Fatty Acid Status and Inflammatory Markers.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05120791
Acronym
MIA_E
Enrollment
20
Registered
2021-11-15
Start date
2022-07-31
Completion date
2022-08-31
Last updated
2022-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Well Aging

Keywords

Microalgae, omega-3 fatty acids, Micronutrients, carotinoids, Inflammation

Brief summary

Investigation of the microalgae Phaeodactylum as food with regard to the uptake of omega-3 fatty acids and effects on various blood parameters in relation to age. Bioavailability and excretion of nutrients and their effects on fatty acid status and inflammatory markers.

Detailed description

Due to a multifaceted redesign of all areas of life, older people face many nutritional challenges, such as cognitive change, sarcopenia and micronutrient deficiency. In addition to age-associated diseases, cognitive decline is usually a precursor to neurodegenerative processes, such as Alzheimer's disease. The full molecular mechanisms are still unknown, but classic aging mechanisms, such as oxidative stress and subclinical inflammation, play a role. Due to the changed life situation, there is a reduced need for energy, while the need for nutrients remains, which greatly increases the risk of malnutrition in old age. This results in an increasing prevalence of sarcopenia. The decrease in muscle mass and strength leads to functional limitations in the elderly and also promotes oxidative stress. This increases the need for antioxidant nutrients such as carotenoids and vitamins. Studies show that age-related chronic subclinical inflammation, such as occurs in the context of an omega-6 fatty acid (-FS) emphasized diet, plays a central role in the pathogenesis of age-associated diseases Due to this, the microalgae PT could be a goud supplier of nutrients like omega-3 FS, especially eicosapentaenoic acid (EPA), which is otherwise found mainly in fatty fish, and Fucoxanthin, an antioxidant. The investigator study the change of omega-3, -6 and -9 FS in blood plasma, in erythrocytes, as well as the change of fucoxanthin and beta-carotene. The investigator measure blood parameters for safety and control the influence on the intestinal barrier.

Interventions

DIETARY_SUPPLEMENTPlacebo vegetable bouillon

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)

DIETARY_SUPPLEMENTmicroalgae phaeodactylum

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum

DIETARY_SUPPLEMENTFrom the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)

DIETARY_SUPPLEMENTA combination of the vegetable bouillon, the microalgae and the beta-Glucan

14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)

Sponsors

University of Hohenheim
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

4 arm parallel groups

Eligibility

Sex/Gender
ALL
Age
65 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

Age ≥60 ≤90 years, weight ≥50 kg, generally healthy * Signed informed consent form * Willingness to follow the prescribed diet for the duration of the study * No participation in any other clinical trial (current or within the last 30 days)

Exclusion criteria

* Taking intestinal therapeutics, antibiotics, immunosuppressants or similar. (if necessary, decision on a case-by-case basis) * Pregnancy/breastfeeding * Relevant violations of the dietary protocol * Occurrence of relevant diseases (if necessary, individual case decision) * Withdrawal of consent * Placement in a clinic or similar facility due to official or court order

Design outcomes

Primary

MeasureTime frameDescription
Change in omega-6/omega-3 ratio (plasma level basis)14 daysfatty acid chromatographic measurement

Secondary

MeasureTime frameDescription
Omega-3 fatty acid index14 daysfatty acid chromatographic measurement in red blood cells
Uptake of fucoxanthin and beta-carotene14 dayschromatographic measurement in plasma
Inflammation (CRP)14 daysmeasurement in blood serum

Other

MeasureTime frameDescription
Markers for oxidative stress14 dayslipid hydroperoxides)
Albumin14 daysMeasurement in serum
weight14 daysin kilograms
FFQ- Food frequence questionnaire4 weeksFood questionnaire about the general eating of the last 4 weeks

Countries

Germany

Contacts

Primary ContactStephan C Bischoff, Prof. Dr
bischoff.stephan@uni-hohenheim.de0711 459 24101
Backup ContactLena Stiefvatter, M.SC
lena.stiefvatter@uni-hohenheim.de071145924881

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026